KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Deferred Taxes: 2011-2025

Historic Deferred Taxes for Vertex Pharmaceuticals (VRTX) over the last 13 years, with Sep 2025 value amounting to -$235.9 million.

  • Vertex Pharmaceuticals' Deferred Taxes fell 91.32% to -$235.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$489.7 million, marking a year-over-year increase of 7.85%. This contributed to the annual value of -$348.8 million for FY2024, which is 34.99% up from last year.
  • Vertex Pharmaceuticals' Deferred Taxes amounted to -$235.9 million in Q3 2025, which was down 107.29% from -$113.8 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Deferred Taxes registered a high of $148.1 million during Q4 2022, and its lowest value of -$237.9 million during Q2 2021.
  • Its 3-year average for Deferred Taxes is -$129.7 million, with a median of -$123.3 million in 2024.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Deferred Taxes soared by 453.46% in 2022, and later slumped by 821.95% in 2023.
  • Vertex Pharmaceuticals' Deferred Taxes (Quarterly) stood at -$41.9 million in 2021, then skyrocketed by 453.46% to $148.1 million in 2022, then crashed by 188.45% to -$131.0 million in 2023, then skyrocketed by 139.39% to $51.6 million in 2024, then crashed by 91.32% to -$235.9 million in 2025.
  • Its last three reported values are -$235.9 million in Q3 2025, -$113.8 million for Q2 2025, and -$191.6 million during Q1 2025.